169 related articles for article (PubMed ID: 21788135)
21. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
Pagare PP; Li M; Zheng Y; Kulkarni AS; Obeng S; Huang B; Ruiz C; Gillespie JC; Mendez RE; Stevens DL; Poklis JL; Halquist MS; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2022 Mar; 65(6):5095-5112. PubMed ID: 35255685
[TBL] [Abstract][Full Text] [Related]
24. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
26. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
[TBL] [Abstract][Full Text] [Related]
27. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
Neumeyer JL; Peng X; Knapp BI; Bidlack JM; Lazarus LH; Salvadori S; Trapella C; Balboni G
J Med Chem; 2006 Sep; 49(18):5640-3. PubMed ID: 16942040
[TBL] [Abstract][Full Text] [Related]
28. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
29. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
30. Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.
Wang H; Zaidi SA; Zhang Y
Bioorg Med Chem; 2017 Apr; 25(8):2463-2471. PubMed ID: 28302509
[TBL] [Abstract][Full Text] [Related]
31. Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans.
Cheng K; Lee YS; Rothman RB; Dersch CM; Bittman RW; Jacobson AE; Rice KC
J Med Chem; 2011 Feb; 54(4):957-69. PubMed ID: 21247164
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
33. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
[TBL] [Abstract][Full Text] [Related]
36. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
[TBL] [Abstract][Full Text] [Related]
37. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
[TBL] [Abstract][Full Text] [Related]
38. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
40. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
Fulton BS; Knapp BL; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2010 Mar; 20(5):1507-9. PubMed ID: 20144870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
